Percentage of JAK2V617F/JAK2total in the cDNA of CD34+ cells and CD33+ cells isolated from the PB of patients with PV and healthy subjects mobilized with G-CSF
Cells . | PV1 . | PV2 . | PV3 . | PV4 . | PV7 . | PV8 . | PV9 . | PV10 . |
|---|---|---|---|---|---|---|---|---|
| CD34+, % | 85.0 | 34.6 | 98.7 | 71.0 | 71.0 | 76.6 | 100 | 83.9 |
| CD33+, % | 60.9 | 30.7 | 71.4 | 57.1 | 72.9 | 67.9 | 100 | 80.5 |
Cells . | PV1 . | PV2 . | PV3 . | PV4 . | PV7 . | PV8 . | PV9 . | PV10 . |
|---|---|---|---|---|---|---|---|---|
| CD34+, % | 85.0 | 34.6 | 98.7 | 71.0 | 71.0 | 76.6 | 100 | 83.9 |
| CD33+, % | 60.9 | 30.7 | 71.4 | 57.1 | 72.9 | 67.9 | 100 | 80.5 |
The purity of the CD34+ cells and CD33+ cells was 95% or greater. Values are JAK2V617F mutant allele/JAK2total allele × 100 in the cDNA. JAK2V617F/JAK2total was determined according to the mean ΔCt and the standard curve by real-time quantitative PCR.
*G-CSF—mobilized health subjects 1, 2, and 3 had 0% CD34+ and D33+ cells.